PET/CT and choline: diagnosis and staging.

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Background:

• Prostate cancer is a leading cause of cancer death in men, necessitating accurate early diagnosis and staging.
• Conventional imaging techniques like MRI and CT have limitations in detecting primary prostate cancer.
• Molecular imaging with PET and PET/CT offers potential for improved detection and localization.

Purpose of the Study:

• To evaluate the role of [11C]- and [18F]-labeled choline PET and PET/CT in diagnosing primary and recurrent prostate cancer.
• To assess the diagnostic accuracy, sensitivity, and specificity of choline PET/CT for primary prostate cancer.
• To determine the current and future clinical utility of choline PET/CT in prostate cancer management.

Main Methods:

• Review of studies evaluating [11C]- and [18F]-labeled choline PET and PET/CT for prostate cancer imaging.
• Analysis of diagnostic performance in primary and recurrent prostate cancer detection.
• Comparison with conventional imaging modalities (TRUS, CT, MRI).

Main Results:

• Choline PET/CT shows increasing importance for detecting recurrent prostate cancer.
• Diagnostic accuracy for primary prostate cancer is moderate, influenced by tumor size and configuration.
• Limited sensitivity for microcarcinomas and specificity issues in differentiating benign prostatic conditions exist.
• Current routine use as a first-line screening for primary prostate cancer is not recommended.

Conclusions:

• Choline PET/CT is valuable for staging recurrent prostate cancer and may aid in re-biopsy guidance for suspected cases with negative biopsies.
• Its role in primary prostate cancer diagnosis is limited by detection challenges for small tumors and differentiation from benign conditions.
• Future applications may include patient stratification for primary surgery and radiation therapy.